Redx Pharma reaches pre-clinical proof of concept stage with oncology lead
Chronic Lymphocytic Leukaemia (CLL) patients commonly develop resistance to gold-standard?therapy (the?irreversible Bruton’s Tyrosine Kinase [BTK] inhibitor,?ibrutinib)?due to a?genetic mutation. ?
Redx’s new candidate is?a reversible BTK inhibitor and could target?resistant CLL?and other blood cancers.
Could be a significant step in the potential advancement of CLL treatment.
Cutting edge oncology research-Redx's experimental BTK inhibitor for resistant CLL shows progress. #3SixtyPharmaSME https://t.co/3YcmncRkYz
— db (@3SixtyPharma) May 25, 2016